Delivery systems and local administration routes for therapeutic siRNA. - Test2 - elhamkhani - TriplyDB

Delivery systems and local administration routes for therapeutic siRNA.

Delivery systems and local administration routes for therapeutic siRNA.

http://www.wikidata.org/entity/Q38076344

about

Technologies for controlled, local delivery of siRNA Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach.Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.In silico design and enzymatic synthesis of functional RNA nanoparticles.siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury.Lentivirus-mediated short hairpin RNA interference targeting TNF-alpha in macrophages inhibits particle-induced inflammation and osteolysis in vitro and in vivo Tyrosine-mutated AAV2-mediated shRNA silencing of PTEN promotes axon regeneration of adult optic nerve Short-interference RNAs: becoming medicines.In vivo delivery of miRNAs for cancer therapy: challenges and strategies.Carrier-free Gene Silencing by Amphiphilic Nucleic Acid Conjugates in Differentiated Intestinal Cells.TGF-β1 Induces Polypyrimidine Tract-Binding Protein to Alter Fibroblasts Proliferation and Fibronectin Deposition in Keloid.Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene.Emerging therapies in allergic conjunctivitis and dry eye syndrome.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies.Cationic cell-penetrating peptides as vehicles for siRNA delivery.Nonionic surfactant vesicles for delivery of RNAi therapeutics.Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs.Palladium-Mediated Labeling of Nucleic Acids.Development of Guanidinium-Rich Protein Mimics for Efficient siRNA Delivery into Human T Cells.Ki67 targeted strategies for cancer therapy.Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran.Stimuli responsive polymer-based strategies for polynucleotide delivery

P2860

Q28087657-26DA7A63-0EC1-43ED-B8F3-3AA08A6FC798 Q33560548-0C934049-9881-41FC-8FDB-6FF8ABD6650E Q33627888-36AE1A5A-3FFE-4CF0-9641-3B883387C5CC Q33791733-BEBEDF91-44A6-4B35-B605-EB2F5BFEC53B Q35590281-CB5214F5-7384-42EC-AD1B-DF1115F6C733 Q36094154-98EE909B-B7C8-4147-A0ED-55E5EA49F9CA Q36166825-01DA8CE6-F5F9-43CD-85C2-322A35F8D69A Q36316471-A5412B34-1A33-42D4-AEC3-9F4553627360 Q36347546-18C44B39-B4EC-40B5-AC7B-4480E1BBC8EE Q37228217-23121746-254D-4041-A1B2-2CFB54A33CB6 Q37325084-CBD3E0AE-079A-47C5-9174-687F9F0EAA72 Q37449229-FA24AA89-1228-42B6-BCC0-C97688F56AF4 Q37718210-88D0B291-9BBA-4A63-AAB0-E7C90EAA062E Q38119024-50177723-52EA-448C-B29D-85EDB3090A13 Q38183852-C53751C3-5C92-4D83-AB44-1905D7470847 Q38198590-E32EB63F-C3ED-433D-ACBB-0F946DE34505 Q38495028-3617EDFD-5CC2-4E96-B6E4-A9E30EAEC401 Q38571809-512C4020-CD32-46E8-B48A-A009D286CAF7 Q38889289-4DF41DDB-1890-475F-A85D-D8C3CE650A68 Q39045835-120996A5-42B1-4389-BEFB-6A5015DA36C4 Q42222936-A19DBFCA-1B92-4A69-979E-5C55D04EC3D5 Q45873470-88AF7960-DDA2-4E52-A15A-C70400B3DE01 Q47106501-ADB65140-5AA1-494C-BE84-F78263E04C67 Q57371723-15C8B8CF-4A88-42BB-99D9-33CA06D5F067

P2860

Delivery systems and local administration routes for therapeutic siRNA.

http://www.wikidata.org/entity/Q38076344

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Delivery systems and local administration routes for therapeutic siRNA.

@en

type

label

Delivery systems and local administration routes for therapeutic siRNA.

@en

prefLabel

Delivery systems and local administration routes for therapeutic siRNA.

@en

P1433

Q38076344-027C4303-5EB4-40D1-B8C2-4390C396AFA1

P1476

Q38076344-B28202E6-330D-4649-B887-672170F4016F

P2093

Q38076344-1BE9C7E6-7740-4CE7-89D8-EED5125F8137

Q38076344-3F6ECC5E-244A-4D1C-9B53-1E9E5835DB20

Q38076344-693F636C-8D6E-4755-AA91-BB4DD8541C24

Q38076344-6BBE8555-1C0B-402E-898D-FAB90F0F006E

Q38076344-A476F935-A594-4886-AAEB-57E188B05654

Q38076344-B952371C-F85F-46C8-A080-CBB1C1041702

P2860

Q38076344-04CCBF29-00E0-49C3-91C3-FC71B5037BE4

Q38076344-057B6314-9C03-4579-B694-BC6FFC1C819C

Q38076344-058D403D-51C0-473B-B41C-12E2B94E231C

Q38076344-06A1EE95-66AC-4CE3-AF79-3B96CB8D2AA5

Q38076344-0AC79CAB-AD5F-495D-86ED-8DC95FA6292B

Q38076344-143184F4-59CB-4957-9C46-6E26019940EA

Q38076344-149CCD66-FEB1-4762-89DF-486ECFC6142B

Q38076344-150F98D7-9462-4C44-9D22-975607ED3BD0

Q38076344-1580D00A-FBD6-4CED-9452-07E74173FEA2

Q38076344-168F316B-9B2C-48B6-90CF-381D7F2ACDBF

P304

Q38076344-5FAC7F83-5F4E-480E-A21E-35AAAC70E0F1

P31

Q38076344-3E12B2CC-5BEB-43FE-85BE-1371B32DD0D4

P356

Q38076344-981C8EED-FD06-470F-8C53-652BD048ECD2

P433

Q38076344-15EC6CC2-15E5-4A8F-9409-42E807AA1E43

P478

Q38076344-30C9A388-0465-49EC-854C-A552E56C19A0

P50

Q38076344-557D1FF7-009A-47A8-A818-03B8997B62B0

P577

Q38076344-7F3152FA-65A4-4124-A9EA-06A4FCCF008D

P5875

Q38076344-15684CFE-66CE-40CE-9926-2CCB48B88266

P698

Q38076344-9D40C01D-486A-4A5F-B5E6-DF6CB940379E

P356

S11095-013-0971-1

P1433

Pharmaceutical Research

P1476

Delivery systems and local administration routes for therapeutic siRNA.

@en

P2093

Danielle de Macedo Mano

http://www.w3.org/2001/XMLSchema#string

Fabiana Testa Moura de Carvalho Vicentini

http://www.w3.org/2001/XMLSchema#string

Lívia Vieira Depieri

http://www.w3.org/2001/XMLSchema#string

Maria Vitória Lopes Badra Bentley

http://www.w3.org/2001/XMLSchema#string

Raquel Petrilli

http://www.w3.org/2001/XMLSchema#string

Thais Fedatto Abelha

http://www.w3.org/2001/XMLSchema#string

P2860

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Barrier function of the skin: "la raison d'être" of the epidermis

Beta-defensin-2 promotes resistance against infection with P. aeruginosa

Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain

Current status and future potential of transdermal drug delivery

Therapeutic potential of RNA interference for neurological disorders

Enhancement of topical small interfering RNA delivery and expression by low-fluence erbium:YAG laser pretreatment of skin.

MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier.

Translocation of cell penetrating peptide engrafted nanoparticles across skin layers

P304

915-931

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-013-0971-1

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Lívia Neves Borgheti-Cardoso

P577

2013-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235367479

http://www.w3.org/2001/XMLSchema#string

P698

23344907

http://www.w3.org/2001/XMLSchema#string